查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1561542

2024-2032 年胃輕癱藥物市場報告（依疾病類型、藥物類別、配銷通路和地區）

Gastroparesis Drugs Market Report by Disease Type, Drug Class, Distribution Channel, and Region 2024-2032
出版日期: | 出版商: IMARC | 英文 143 Pages | 商品交期: 2-3個工作天內

價格

2023年全球胃輕癱藥物IMARC Group規模達65億美元。糖尿病性胃輕癱盛行率的上升、藥物開發技術的進步、醫療保健專業人員和患者意識的提高、醫療保健投資的快速成長、臨床試驗的增加、糖尿病和帕金森氏症等慢性病的激增以及監管支持是推動市場成長的一些因素。

胃輕癱藥物市場分析：

  • 主要市場促進因素：糖尿病盛行率的增加大大增加了胃輕癱的盛行率，推動了市場的成長。診斷解決方案的改進進一步支持了這一點，使患者能夠及早識別疾病。此外，易患胃輕癱的老年人口不斷增加是推動市場向前發展的另一個因素。與此一致的是，先進給藥系統的使用不斷增加，以及醫療保健提供者和患者對胃輕癱的認知不斷提高，正在促進市場成長。此外，醫療基礎設施的快速擴張，尤其是在發展中地區，以及政府對胃腸道研究的舉措和資助，正在創造積極的胃輕癱藥物市場前景。
  • 主要市場趨勢：對個人化醫療的偏好轉變是主要市場趨勢之一。此外，機器學習（ML）和人工智慧（AI）在藥物發現中的整合加快了新療法開發的步伐，從而推動了市場的成長。此外，對微創手術（MIS）的需求不斷成長，推動了先進藥物輸送系統的使用，這是推動市場擴張的另一個因素。此外，對門診護理和家庭治療的日益重視以及對胃輕癱研究的投資不斷增加正在促進市場成長。
  • 地理趨勢：由於糖尿病盛行率迅速上升、先進治療方法的不斷發展以及強大的醫療基礎設施，北美佔據了最大的市場佔有率。根據胃輕癱藥物市場預測，由於德國、英國和法國等國家主要市場參與者的存在，歐洲也佔有相當大的市場佔有率。在亞太地區，醫療保健投資的增加、患者數量的增加以及對胃輕癱的認知的提高正在促進市場的成長。
  • 競爭格局：胃輕癱藥物產業的一些主要市場參與者包括 Abbott Laboratories、Abbvie Inc.、AstraZeneca Plc、Bausch Health Companies Inc.、Becton Dickinson and Company、Boston Scientific Corporation、Evoke Pharma、Medtronic plc、Neurogastrx Inc.、賽諾菲(Sanofi SA)、武田藥品工業株式會社(Takeda Pharmaceutical Company Limited) 和Theravance Biopharma 等。
  • 挑戰與機會：根據市場概況，胃輕癱藥物市場主要受到對病理生理學的有限了解以及與現有藥物相關的副作用的限制。然而，生物技術和基因組學的快速進步以及新標靶療法的開發為市場擴張提供了利潤豐厚的機會。此外，全球胃輕癱診斷的改善和糖尿病病例的不斷增加正在刺激市場成長。

胃輕癱藥物市場趨勢：

胃輕癱盛行率增加

胃輕癱盛行率不斷上升，尤其是糖尿病患者，正在加速市場成長。 2021年，印度約有7,490萬年齡在20-79歲之間的糖尿病患者，預計到2045年將達到1.249億。了為市場成長帶來了巨大的推動力。此外，主要製藥公司正在積極致力於開發新的標靶治療方案，這進一步為市場創造了積極的前景。

藥物開發技術的進步

管道中產品數量的不斷增加以及新產品變體的開發正在促進市場成長。此外，為提高胃輕癱療法的療效和安全性而對藥物研發（R＆D）的投資激增正在推動市場成長。胃輕癱藥物市場最近的機會，例如高通量篩選、計算和個人化醫療的出現，使得能夠精確、快速地識別潛在候選藥物，正在為市場成長提供動力。除此之外，藥物輸送系統的進步，例如緩釋製劑和新型藥物輸送機制，正在實現藥物的有效給藥和吸收，推動市場成長。

醫療保健專業人員和患者的意識不斷提高

醫療保健專業人員和患者對胃輕癱的認知不斷增強，大大促進了市場的成長。由於隨後意識的提高，患者得到了更準確的診斷，這進一步為市場成長提供了相當大的推動力。此外，胃腸病學家等醫療保健專業人員越來越敏銳地意識到這些症狀，這進一步有助於更快地識別胃輕癱，從而更好地照顧患者。此外，患者對胃輕癱症狀和治療的認知不斷提高，以及新型治療方案的出現，正在推動胃輕癱藥物的需求。

胃輕癱藥物市場細分：

IMARC Group提供了每個細分市場的主要趨勢的分析，以及 2024-2032 年全球、區域和國家層面的預測。我們的報告根據疾病類型、藥物類別和配銷通路對市場進行了分類。

按疾病類型細分：

  • 糖尿病胃輕癱
  • 特發性胃輕癱
  • 術後胃輕癱
  • 其他

特發性胃輕癱佔大部分市場佔有率

該報告根據疾病類型對市場進行了詳細的細分和分析。這包括糖尿病性胃輕癱、特發性胃輕癱、術後胃輕癱等。根據該報告，特發性胃輕癱佔最大部分。

特發性胃輕癱領域的發展是由於人們越來越認知到該疾病的影響以及對有效治療解決方案的需求。特發性胃輕癱無法確定根本原因，由於其不可預測的性質和嚴重程度，給患者和醫療保健提供者帶來了重大挑戰。臨床醫生對特發性胃輕癱的認知和理解的提高使得診斷更加準確，並專注於開發標靶治療。診斷技術的進步，例如改進的影像和運動測試，正在增強識別特發性胃輕癱病例並將其與其他胃腸道疾病區分開來的能力，從而促進胃輕癱藥物市場的成長。此外，針對特發性胃輕癱的研究經費和臨床試驗的增加正在推動藥物開發的創新，帶來新的治療選擇。

按藥物類別細分：

  • 促動力劑
  • 止吐劑
  • 肉毒桿菌注射

促動力劑佔據產業最大佔有率

報告還提供了基於藥物類別的詳細市場細分和分析。這包括促動力劑、止吐劑和肉毒桿菌注射。報告稱，促動力劑佔據最大的市場佔有率。

胃輕癱藥物市場中的促胃動力藥物細分市場是由幾個關鍵因素驅動的，例如胃輕癱盛行率不斷增加，特別是在糖尿病和老年人群中，這對有效的促胃動力療法產生了強烈需求。促動力劑可增強胃動力並促進胃排空，對於控制胃輕癱症狀（包括噁心和嘔吐）至關重要。藥物開發的重大進步導致促胃動力配方的改進、功效增強和副作用減少，從而增加了胃輕癱藥物市場收入。正在進行的針對促動力劑的研究和臨床試驗有助於更好地了解其機制和潛在益處，從而擴大其臨床應用。此外，醫療保健專業人員和患者對胃輕癱的認知不斷增強，強調了對有效治療的需求，進一步推動了對促胃動力藥物的需求。

按配銷通路分類：

  • 醫院和診所
  • 藥局
  • 網路商店

醫院和診所是主要的細分市場

該報告根據配銷通路對市場進行了詳細的細分和分析。這包括醫院和診所、藥房和網路商店。報告稱，醫院和診所是最大的部分。

胃輕癱藥物市場的醫院和診所部分是由對治療胃輕癱的專業醫療護理和先進治療選擇不斷成長的需求所推動的。該細分市場受益於胃輕癱盛行率的不斷上升，特別是在糖尿病患者中，因此需要更全面和更頻繁的醫療干預措施。醫院和診所提供一系列診斷和治療服務，包括專門的胃腸病科和先進的影像技術，這對於胃輕癱的準確診斷和有效管理至關重要。此外，糖尿病和帕金森氏症等慢性疾病的增加（通常導致胃輕癱）進一步推動了對醫院治療的需求。

按地區分類：

  • 北美洲
    • 美國
    • 加拿大
  • 亞太
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲

北美市場領先，胃輕癱藥物市佔率最大

該報告還對所有主要區域市場進行了全面分析，其中包括北美（美國和加拿大）；亞太地區（中國、日本、印度、韓國、澳洲、印尼等）；歐洲（德國、法國、英國、義大利、西班牙、俄羅斯等）；拉丁美洲（巴西、墨西哥等）；以及中東和非洲。報告稱，北美是胃輕癱藥物最大的區域市場。

北美區域市場受到胃輕癱盛行率迅速上升的推動，尤其是在糖尿病族群中，這極大地影響了對有效治療的需求。糖尿病的高發生率是一個主要因素，因為糖尿病胃輕癱是一種常見的併發症。此外，胃輕癱藥物市場的最新發展和進步，例如高通量篩選和新型藥物輸送系統，提高了胃輕癱藥物的功效和安全性，有助於市場擴張。除此之外，該地區還受益於強大的醫療基礎設施和對研發的大量投資，從而能夠更快地推出創新療法。此外，醫療保健專業人員和患者對胃輕癱及其管理的認知不斷提高，正在加強市場成長，從而實現更早的診斷和更積極的治療方法。

（請注意，這只是關鍵參與者的部分列表，報告中提供了完整列表。）

  • 主要胃輕癱藥物公司正在積極參與多項策略性舉措，以提升其地位並滿足對有效治療日益成長的需求。他們正在大力投資研發 (R&D)，以發現和開發更有效地針對胃輕癱潛在機制的新藥。這些公司專注於創新藥物配方，包括緩釋和新型遞送系統，以提高治療的功效和患者的依從性。我們正在尋求與研究機構和學術組織的合作和夥伴關係，以利用外部專業知識和資源，從而加速新療法的開發。此外，領先企業正在擴大其臨床試驗計劃，以測試新的候選藥物並收集關鍵資料以支持監管部門的批准。他們也積極尋求監管支持，以加快新療法的核准流程，旨在更快地將創新解決方案推向市場。

胃輕癱藥物市場新聞：

  • 2023 年，專注於治療胃腸道 (GI) 疾病的專業製藥公司 Evoke Pharma 宣布其藥物 GIMOTI 的一項新專利已在 FDA 橙皮書中列出。該專利名為“甲氧氯普胺鼻用配方”，將GIMOTI 的專利保護期限延長至2029 年。其在治療糖尿病胃輕癱的市場中的地位。
  • 2023 年，Enterra Medical 宣布其 Enterra(R) II 系統已獲得 FDA 批准用於 MR 有條件使用。這種先進的胃輕癱治療方法包括 Enterra 37800 神經刺激器和 Enterra Therapy 4351-35 單極導線，現在允許患者在特定條件下接受頭部和四肢的 MRI 掃描。

本報告回答的關鍵問題

  • 2023年全球胃輕癱藥物市場規模是多少
  • 2024-2032年全球胃輕癱藥物市場的預期成長率是多少
  • COVID-19 對全球胃輕癱藥物市場有何影響
  • 推動全球胃輕癱藥物市場的關鍵因素是什麼
  • 根據疾病類型，全球胃輕癱藥物市場的細分如何
  • 根據藥物類別，全球胃輕癱藥物市場的細分如何
  • 基於配銷通路，全球胃輕癱藥物市場的細分如何
  • 全球胃輕癱藥物市場的重點區域有哪些
  • 誰是全球胃輕癱藥物市場的主要參與者/公司

本報告回答的關鍵問題

  • 2023年全球胃輕癱藥物市場規模？ 2024-2032年全球胃輕癱藥物市場的預期成長率為何？
  • COVID-19 對全球胃輕癱藥物市場有何影響？
  • 推動全球胃輕癱藥物市場的關鍵因素是什麼？
  • 根據疾病類型，全球胃輕癱藥物市場的細分如何？
  • 根據藥物類別，全球胃輕癱藥物市場的細分如何？
  • 根據配銷通路，全球胃輕癱藥物市場的細分如何？
  • 全球胃輕癱藥物市場的重點區域有哪些？
  • 全球胃輕癱藥物市場的主要參與者/公司有哪些？

目錄

第1章：前言

第 2 章：範圍與方法

  • 研究目的
  • 利害關係人
  • 數據來源
    • 主要來源
    • 二手資料
  • 市場預測
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第 3 章：執行摘要

第 4 章：簡介

  • 概述
  • 主要行業趨勢

第 5 章：全球胃輕癱藥物市場

  • 市場概況
  • 市場表現
  • COVID-19 的影響
  • 市場預測

第 6 章：市場區隔：依疾病類型

  • 糖尿病胃輕癱
    • 市場趨勢
    • 市場預測
  • 特發性胃輕癱
    • 市場趨勢
    • 市場預測
  • 術後胃輕癱
    • 市場趨勢
    • 市場預測
  • 其他
    • 市場趨勢
    • 市場預測

第 7 章：市場區隔：依藥物類別

  • 促動力劑
    • 市場趨勢
    • 市場預測
  • 止吐劑
    • 市場趨勢
    • 市場預測
  • 肉毒桿菌注射
    • 市場趨勢
    • 市場預測

第 8 章：市場區隔：按配銷通路

  • 醫院和診所
    • 市場趨勢
    • 市場預測
  • 藥局
    • 市場趨勢
    • 市場預測
  • 網路商店
    • 市場趨勢
    • 市場預測

第 9 章：市場區隔：按地區

  • 北美洲
    • 美國
    • 加拿大
  • 亞太
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲
    • 市場趨勢
    • 市場細分：按國家/地區
    • 市場預測

第 10 章：SWOT 分析

  • 概述
  • 優勢
  • 弱點
  • 機會
  • 威脅

第 11 章：價值鏈分析

第 12 章：波特五力分析

  • 概述
  • 買家的議價能力
  • 供應商的議價能力
  • 競爭程度
  • 新進入者的威脅
  • 替代品的威脅

第 13 章：價格分析

第14章：競爭格局

  • 市場結構
  • 關鍵參與者
  • 關鍵參與者簡介
    • Abbott Laboratories
    • Abbvie Inc.
    • AstraZeneca Plc
    • Bausch Health Companies Inc.
    • Becton Dickinson and Company
    • Boston Scientific Corporation
    • Evoke Pharma
    • Medtronic plc
    • Neurogastrx Inc.
    • Sanofi SA
    • Takeda Pharmaceutical Company Limited
    • Theravance Biopharma
Product Code: SR112024A4608

The global gastroparesis drugs market size reached US$ 6.5 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 9.5 Billion by 2032, exhibiting a growth rate (CAGR) of 4.3% during 2024-2032. The rising prevalence of diabetic gastroparesis, advancements in drug development technologies, increasing awareness among healthcare professionals and patients, burgeoning healthcare investments, growing clinical trials, surging chronic conditions like diabetes and Parkinson's, and regulatory support are some of the factors propelling the market growth.

Gastroparesis Drugs Market Analysis:

  • Major Market Drivers: The increasing prevalence of diabetes has considerably boosted the prevalence of gastroparesis, which is fueling the market growth. This is further supported by the improvements in diagnosis solutions, which enable early disease identification among patients. Moreover, the escalating geriatric population susceptible to gastroparesis is another factor propelling the market forward. In line with this, the growing use of advanced drug delivery systems and surging awareness about gastroparesis among healthcare providers and patients are facilitating the market growth. Furthermore, the rapid expansion of healthcare infrastructure, especially in developing regions, and government initiatives and funding for gastrointestinal research are creating a positive gastroparesis drugs market outlook.
  • Key Market Trends: The shifting preference toward personalized medicine is one of the primary market trends. Moreover, the integration of machine learning (ML) and artificial intelligence (AI) in drug discovery to boost the pace of novel therapy development is bolstering the market growth. Additionally, the increasing demand for minimally invasive surgery (MIS) has fueled the use of advanced drug delivery systems, which is another factor driving market expansion. Furthermore, the escalating emphasis on outpatient care and home-based treatments and burgeoning investments in gastroparesis research are facilitating the market growth.
  • Geographical Trends: North America holds the largest market share due to the burgeoning prevalence of diabetes, the continuous development of advanced treatments, and the presence of robust healthcare infrastructure. As per the gastroparesis drugs market forecast, Europe also holds a considerable market share backed by the presence of key market players in countries, such as Germany, the UK, and France. In the Asia Pacific, rising healthcare investments, growing patient numbers, and increasing awareness regarding gastroparesis are fostering the market growth.
  • Competitive Landscape: Some of the major market players in the gastroparesis drugs industry include Abbott Laboratories, Abbvie Inc., AstraZeneca Plc, Bausch Health Companies Inc., Becton Dickinson and Company, Boston Scientific Corporation, Evoke Pharma, Medtronic plc, Neurogastrx Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited, and Theravance Biopharma, among many others.
  • Challenges and Opportunities: As per the market overview, the gastroparesis drugs market is primarily restrained by the limited understanding of pathophysiology and the side effects associated with currently available medications. However, the rapid advancement in biotechnology and genomics and the development of new targeted therapies are presenting lucrative opportunities for market expansion. Furthermore, the improving diagnosis of gastroparesis and burgeoning cases of diabetes across the globe are stimulating the market growth.

Gastroparesis Drugs Market Trends:

Increasing Prevalence of Gastroparesis

The escalating prevalence of gastroparesis, especially in diabetes patients, is accelerating the market growth. In 2021 India had about 74.9 million people with diabetes aged between 20-79, which is expected to reach 124.9 million by 2045. Moreover, the increasing number of patients with diabetes has burgeoned the need for efficient treatment and management, which is further providing a considerable thrust to the market growth. Additionally, the key pharmaceutical companies are actively working to develop new and targeted therapy options, which is further creating a positive outlook for the market.

Advancements in Drug Development Technologies

The growing number of products in the pipeline and the development of new product variants are augmenting the market growth. Furthermore, the surging investments in pharmaceutical research and development (R&D) to improve the efficacy and safety of gastroparesis therapies are fueling the market growth. The gastroparesis drugs market recent opportunities, such as the advent of high-throughput screening, computational and personalized medicine, enabling precise and quick identification of potential candidates are providing an impetus to the market growth. Apart from this, the advancements in drug delivery systems, such as extended-release formulations and novel drug-delivery mechanisms, are rendering an efficient administration and absorption of medications, thereby impelling the market growth.

Rising Awareness Among Healthcare Professionals and Patients

The growing awareness among both healthcare professionals and patients regarding gastroparesis is significantly facilitating the market growth. Patients with the condition are more accurately diagnosed due to the subsequent increase in awareness, which further provides a considerable thrust to the market growth. Additionally, healthcare professionals, such as gastroenterologists, are becoming more acutely aware of the symptoms, which further helps recognize gastroparesis sooner, leading to better patient care. Moreover, burgeoning patient awareness about the symptoms and treatment of gastroparesis and the availability of novel treatment options are propelling the gastroparesis drugs demand.

Gastroparesis Drugs Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the global, regional, and country levels for 2024-2032. Our report has categorized the market based on disease type, drug class, and distribution channel.

Breakup by Disease Type:

  • Diabetic Gastroparesis
  • Idiopathic Gastroparesis
  • Post-surgical Gastroparesis
  • Others

Idiopathic gastroparesis accounts for the majority of the market share

The report has provided a detailed breakup and analysis of the market based on the disease type. This includes diabetic gastroparesis, idiopathic gastroparesis, post-surgical gastroparesis, and others. According to the report, idiopathic gastroparesis represented the largest segment.

The idiopathic gastroparesis segment is driven by the growing recognition of the condition's impact and the need for effective treatment solutions. Idiopathic gastroparesis, where no underlying cause can be identified, poses significant challenges for patients and healthcare providers due to its unpredictable nature and severity. Increased awareness and understanding of idiopathic gastroparesis among clinicians are leading to more accurate diagnoses and a focus on developing targeted therapies. Advances in diagnostic technologies, such as improved imaging and motility testing, are enhancing the ability to identify idiopathic gastroparesis cases and differentiate them from other gastrointestinal disorders, thereby boosting the gastroparesis drugs market growth. Furthermore, the rise in research funding and clinical trials dedicated to idiopathic gastroparesis is driving innovation in drug development, leading to new therapeutic options.

Breakup by Drug Class:

  • Prokinetic Agents
  • Antiemetic Agents
  • Botulinum Toxin Injections

Prokinetic agents hold the largest share of the industry

A detailed breakup and analysis of the market based on the drug class have also been provided in the report. This includes prokinetic agents, antiemetic agents, and botulinum toxin injections. According to the report, prokinetic agents accounted for the largest market share.

The prokinetic agents segment in the gastroparesis drugs market is driven by several key factors, such as the increasing prevalence of gastroparesis, particularly among diabetic and elderly populations, which creates a strong demand for effective prokinetic therapies. Prokinetic agents, which enhance gastric motility and facilitate stomach emptying, are essential in managing the symptoms of gastroparesis, including nausea and vomiting. Significant advancements in drug development leading to improved prokinetic formulations with enhanced efficacy and fewer side effects are boosting gastroparesis drugs market revenue. The ongoing research and clinical trials focused on prokinetic agents contribute to a better understanding of their mechanisms and potential benefits, thereby expanding their clinical applications. Additionally, the growing awareness of gastroparesis among healthcare professionals and patients underscores the need for effective treatments, further driving the demand for prokinetic agents.

Breakup by Distribution Channel:

  • Hospitals and Clinics
  • Pharmacies
  • Online Stores

Hospitals and clinics represent the leading market segment

The report has provided a detailed breakup and analysis of the market based on the distribution channel. This includes hospitals and clinics, pharmacies, and online stores. According to the report, hospitals and clinics represented the largest segment.

The hospitals and clinics segment in the gastroparesis drugs market is driven by the increasing demand for specialized medical care and advanced treatment options for managing gastroparesis. The segment benefits from the escalating prevalence of gastroparesis, particularly among diabetic patients, necessitating more comprehensive and frequent medical interventions. Hospitals and clinics offer a range of diagnostic and therapeutic services, including specialized gastroenterology departments and advanced imaging technologies, which are crucial for accurate diagnosis and effective management of gastroparesis. Additionally, the rise in chronic conditions such as diabetes and Parkinson's disease, which often lead to gastroparesis, further drives the need for hospital-based treatments.

Breakup by Region:

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

North America leads the market, accounting for the largest gastroparesis drugs market share

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America represents the largest regional market for gastroparesis drugs.

The North America regional market is driven by the burgeoning prevalence of gastroparesis, particularly among the diabetic population, which significantly impacts demand for effective treatments. The high incidence of diabetes is a major contributing factor, as diabetic gastroparesis is a common complication. Additionally, the gastroparesis drugs market recent developments and advancements, such as high-throughput screening and novel drug delivery systems, enhancing the efficacy and safety profiles of gastroparesis medications are aiding in market expansion. Besides this, the region also benefits from robust healthcare infrastructure and significant investments in research and development, enabling faster introduction of innovative treatments. Moreover, the increasing awareness among healthcare professionals and patients about gastroparesis and its management is strengthening the market growth, leading to earlier diagnosis and more proactive treatment approaches.

Competitive Landscape:

  • The market research report has also provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the major market players in the gastroparesis drugs industry include Abbott Laboratories, Abbvie Inc., AstraZeneca Plc, Bausch Health Companies Inc., Becton Dickinson and Company, Boston Scientific Corporation, Evoke Pharma, Medtronic plc, Neurogastrx Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited, Theravance Biopharma, etc.

(Please note that this is only a partial list of the key players, and the complete list is provided in the report.)

  • The key gastroparesis drugs companies are actively engaged in several strategic initiatives to advance their position and address the growing demand for effective treatments. They are investing heavily in research and development (R&D) to discover and develop new drugs that target the underlying mechanisms of gastroparesis more effectively. These companies are focusing on innovative drug formulations, including extended-release and novel delivery systems, to enhance the efficacy and patient compliance of treatments. Collaborations and partnerships with research institutions and academic organizations are being pursued to leverage external expertise and resources, which accelerates the development of new therapies. Additionally, leading players are expanding their clinical trial programs to test new drug candidates and gather crucial data to support regulatory approvals. They are also actively seeking regulatory support to expedite the approval process for new treatments, aiming to bring innovative solutions to market more quickly.

Gastroparesis Drugs Market News:

  • In 2023, Evoke Pharma, a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, announced the FDA Orange Book listing of a new patent for their drug GIMOTI. The patent, titled "Nasal Formulations of Metoclopramide," extends GIMOTI's patent protection through 2029. This addition marks the fourth patent listed for GIMOTI, enhancing its intellectual property portfolio, and securing its position in the market for treating diabetic gastroparesis.
  • In 2023, Enterra Medical announced that its Enterra(R) II System received FDA approval for MR Conditional use. This advanced treatment for gastroparesis, which includes the Enterra 37800 Neurostimulator and Enterra Therapy 4351-35 unipolar leads, now allows patients to undergo MRI scans of the head and extremities under specific conditions.

Key Questions Answered in This Report

  • 1. What was the size of the global gastroparesis drugs market in 2023?
  • 2. What is the expected growth rate of the global gastroparesis drugs market during 2024-2032?
  • 3. What has been the impact of COVID-19 on the global gastroparesis drugs market?
  • 4. What are the key factors driving the global gastroparesis drugs market?
  • 5. What is the breakup of the global gastroparesis drugs market based on the disease type?
  • 6. What is the breakup of the global gastroparesis drugs market based on the drug class?
  • 7. What is the breakup of the global gastroparesis drugs market based on the distribution channel?
  • 8. What are the key regions in the global gastroparesis drugs market?
  • 9. Who are the key players/companies in the global gastroparesis drugs market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Gastroparesis Drugs Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Disease Type

  • 6.1 Diabetic Gastroparesis
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Idiopathic Gastroparesis
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Post-surgical Gastroparesis
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Others
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast

7 Market Breakup by Drug Class

  • 7.1 Prokinetic Agents
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Antiemetic Agents
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Botulinum Toxin Injections
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast

8 Market Breakup by Distribution Channel

  • 8.1 Hospitals and Clinics
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Pharmacies
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Online Stores
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Abbott Laboratories
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
      • 14.3.1.4 SWOT Analysis
    • 14.3.2 Abbvie Inc.
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
      • 14.3.2.4 SWOT Analysis
    • 14.3.3 AstraZeneca Plc
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
      • 14.3.3.4 SWOT Analysis
    • 14.3.4 Bausch Health Companies Inc.
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
      • 14.3.4.4 SWOT Analysis
    • 14.3.5 Becton Dickinson and Company
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
      • 14.3.5.4 SWOT Analysis
    • 14.3.6 Boston Scientific Corporation
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
      • 14.3.6.4 SWOT Analysis
    • 14.3.7 Evoke Pharma
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials
    • 14.3.8 Medtronic plc
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 Financials
      • 14.3.8.4 SWOT Analysis
    • 14.3.9 Neurogastrx Inc.
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
    • 14.3.10 Sanofi S.A.
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
    • 14.3.11 Takeda Pharmaceutical Company Limited
      • 14.3.11.1 Company Overview
      • 14.3.11.2 Product Portfolio
      • 14.3.11.3 Financials
      • 14.3.11.4 SWOT Analysis
    • 14.3.12 Theravance Biopharma
      • 14.3.12.1 Company Overview
      • 14.3.12.2 Product Portfolio
      • 14.3.12.3 Financials
      • 14.3.12.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Gastroparesis Drugs Market: Major Drivers and Challenges
  • Figure 2: Global: Gastroparesis Drugs Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Gastroparesis Drugs Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 4: Global: Gastroparesis Drugs Market: Breakup by Disease Type (in %), 2023
  • Figure 5: Global: Gastroparesis Drugs Market: Breakup by Drug Class (in %), 2023
  • Figure 6: Global: Gastroparesis Drugs Market: Breakup by Distribution Channel (in %), 2023
  • Figure 7: Global: Gastroparesis Drugs Market: Breakup by Region (in %), 2023
  • Figure 8: Global: Gastroparesis Drugs (Diabetic Gastroparesis) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 9: Global: Gastroparesis Drugs (Diabetic Gastroparesis) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 10: Global: Gastroparesis Drugs (Idiopathic Gastroparesis) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 11: Global: Gastroparesis Drugs (Idiopathic Gastroparesis) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 12: Global: Gastroparesis Drugs (Post-surgical Gastroparesis) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 13: Global: Gastroparesis Drugs (Post-surgical Gastroparesis) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 14: Global: Gastroparesis Drugs (Other Disease Types) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 15: Global: Gastroparesis Drugs (Other Disease Types) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 16: Global: Gastroparesis Drugs (Prokinetic Agents) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 17: Global: Gastroparesis Drugs (Prokinetic Agents) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 18: Global: Gastroparesis Drugs (Antiemetic Agents) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 19: Global: Gastroparesis Drugs (Antiemetic Agents) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 20: Global: Gastroparesis Drugs (Botulinum Toxin Injections) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 21: Global: Gastroparesis Drugs (Botulinum Toxin Injections) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 22: Global: Gastroparesis Drugs (Hospitals and Clinics) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 23: Global: Gastroparesis Drugs (Hospitals and Clinics) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 24: Global: Gastroparesis Drugs (Pharmacies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 25: Global: Gastroparesis Drugs (Pharmacies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 26: Global: Gastroparesis Drugs (Online Stores) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 27: Global: Gastroparesis Drugs (Online Stores) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 28: North America: Gastroparesis Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 29: North America: Gastroparesis Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 30: United States: Gastroparesis Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 31: United States: Gastroparesis Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 32: Canada: Gastroparesis Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 33: Canada: Gastroparesis Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 34: Asia-Pacific: Gastroparesis Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 35: Asia-Pacific: Gastroparesis Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 36: China: Gastroparesis Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 37: China: Gastroparesis Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 38: Japan: Gastroparesis Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 39: Japan: Gastroparesis Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 40: India: Gastroparesis Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 41: India: Gastroparesis Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 42: South Korea: Gastroparesis Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 43: South Korea: Gastroparesis Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 44: Australia: Gastroparesis Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 45: Australia: Gastroparesis Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 46: Indonesia: Gastroparesis Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 47: Indonesia: Gastroparesis Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 48: Others: Gastroparesis Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 49: Others: Gastroparesis Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 50: Europe: Gastroparesis Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 51: Europe: Gastroparesis Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 52: Germany: Gastroparesis Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 53: Germany: Gastroparesis Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 54: France: Gastroparesis Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 55: France: Gastroparesis Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 56: United Kingdom: Gastroparesis Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 57: United Kingdom: Gastroparesis Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 58: Italy: Gastroparesis Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 59: Italy: Gastroparesis Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 60: Spain: Gastroparesis Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 61: Spain: Gastroparesis Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 62: Russia: Gastroparesis Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 63: Russia: Gastroparesis Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 64: Others: Gastroparesis Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 65: Others: Gastroparesis Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 66: Latin America: Gastroparesis Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 67: Latin America: Gastroparesis Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 68: Brazil: Gastroparesis Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 69: Brazil: Gastroparesis Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 70: Mexico: Gastroparesis Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 71: Mexico: Gastroparesis Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 72: Others: Gastroparesis Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 73: Others: Gastroparesis Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 74: Middle East and Africa: Gastroparesis Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 75: Middle East and Africa: Gastroparesis Drugs Market: Breakup by Country (in %), 2023
  • Figure 76: Middle East and Africa: Gastroparesis Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 77: Global: Gastroparesis Drugs Industry: SWOT Analysis
  • Figure 78: Global: Gastroparesis Drugs Industry: Value Chain Analysis
  • Figure 79: Global: Gastroparesis Drugs Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Gastroparesis Drugs Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: Gastroparesis Drugs Market Forecast: Breakup by Disease Type (in Million US$), 2024-2032
  • Table 3: Global: Gastroparesis Drugs Market Forecast: Breakup by Drug Class (in Million US$), 2024-2032
  • Table 4: Global: Gastroparesis Drugs Market Forecast: Breakup by Distribution Channel (in Million US$), 2024-2032
  • Table 5: Global: Gastroparesis Drugs Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 6: Global: Gastroparesis Drugs Market: Competitive Structure
  • Table 7: Global: Gastroparesis Drugs Market: Key Players